Pay in 4 interest-free payments of $7.13 Learn more
Ships within 48 hours · Estimated delivery Aug 2 - Aug 7
December 3, 2024 The Ozempic MDL saw a surge in filings, with 79 new cases in November alone
Approval Timeline and Availability CagriSema: Ahead in the Race FDA Submission: December 18, 2025 (NDA filed) Expected FDA Decision: Q4 2026 or Q1 2027 Predicted Launch: Mid-2027 Advantage: 6-12 month head start on retatrutide REDEFINE Program Status: REDEFINE-1: Completed (obesity, 20.4% weight loss) REDEFINE-2: Completed (type 2 diabetes, 13.7% weight loss) REDEFINE-3: Ongoing (cardiovascular outcomes trial) REDEFINE-8: Ongoing (body composition study) High-dose CagriSema (2.4/7.2mg): Starting late 2026 Retatrutide: More Trials Needed FDA Submission: Expected Q4 2026 or Q1 2027 Expected FDA Decision: Late 2027 Predicted Launch: Q1-Q2 2028 TRIUMPH Program Status: TRIUMPH-4: Completed (osteoarthritis, 28.7% weight loss) TRIUMPH-1: Complete 28.3% weight loss (May 2026) TRIUMPH-2: Expected Q3Q4 2026 (obesity + type 2 diabetes) TRIUMPH-3: Expected later 2026 (obesity + cardiovascular disease) TRIUMPH-6: Weight maintenance trial (ongoing) Disadvantage: Needs more trials before submission, 6-12 month delay vs CagriSema
Report any concerning symptoms promptly, including chest pain, severe palpitations, persistent nausea, mood changes, or thoughts of self-harm
Several in vitro and in vivo results have expanded the role of these molecules from potentiating glucose-stimulated insulin secretion to promoting -cell survival under different stressful environments by favoring proliferation, neogenesis and resistance to apoptosis ( via secretion of IGF-2 from the same cells ( In agreement with experimental studies, GLP-1 analogues, particularly liraglutide, sustain the maintenance of -cell function in obese individuals with early T2D, and these effects are presumably independent of weight loss ( Further, experimental data suggest that the pro-survival action of GLP-1RAs may also be mediated by the Akt-dependent stimulation of the mTORC1/S6K1 pathway, the activation of which is dependent upon the IGF-1R, as observed in rodent islet cells ( in vitro , exendin-4 lost the ability to activate this pathway, suggesting that GLP-1 analogues may restore -cell proliferation via autocrine or paracrine activation of IGF-1R ( In concert, these results define a new scenario of action for incretin-based therapy that may involve the adipo-insular axis, linking the weight lowering competence with the sustained protection of -cells from diabetogenic stressors
